US FDA investigates energy levels in external defibrillators
This article was originally published in SRA
The US Food and Drug Administration has told healthcare professionals that it is investigating external biphasic defibrillators with shocks of ?200 Joules after reports suggesting they are ineffective1.
You may also be interested in...
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
If Zolgensma gets the thumbs up from the EMA this week, it will likely get formal EU approval within a couple of months.
BMS should find out mid-2020 whether its new MS drug will be approved in the EU.